



THE PRIMARY CARE COMPANION FOR CNS DISORDERS

Supplementary Material

Article Title: Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Tarragona Catchment Area

Author(s): Ana M. Gaviria, PhD; José Franco, PhD; Guillem Rico, DI; Gerard Muntané, PhD; Cristina Sáez, MD; Vanessa Sánchez-Gistau, PhD; Joan de Pablo, PhD; and Elisabet Vilella, PhD

DOI Number: <https://doi.org/10.4088/PCC.16m02044>

List of Supplementary Material for the article

1. [Table 1](#)
2. [Figure 1](#)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Table 1. Demographic and clinical characteristics of patients with long (≥5 years) and short (<5 years) disease evolution

Variable	≥5 years	<5 years	Statistic p-value
N	1317	329	
Gender			$X^2=9.25, p=0.00236$
Male	884 (67.1%)	250 (76%)	
Female	433 (32.9%)	79 (24%)	
Age (years, mean ± SD)	45.5±13.8	36.9±10.3	$D=0.27, p<0.001$
Marital status			$X^2=15.73, p=0.0034$
Single	918 (69.7%)	215 (65.3%)	
Married / Domestic Partner	175 (13.3%)	46 (14%)	
Separated / Divorced	75 (5.7%)	13 (4%)	
Widowed	20 (1.5%)	1 (0.3%)	
Unknown/Not reported	129 (9.8%)	54 (16.4%)	
Schizophrenia subtype			$X^2=26.48, p<0.001$
Paranoid	941 (71.5%)	260 (79%)	
Hebephrenic	38 (2.9%)	3 (0.9%)	
Catatonic	2 (0.2%)	2 (0.6%)	
Undifferentiated	75 (5.7%)	17 (5.2%)	
Post-schizophrenic depression	-	1 (0.3%)	
Residual	155 (11.8%)	15 (4.6%)	
Simple	47 (3.6%)	13 (4%)	
Other	10 (0.8%)	3 (0.9%)	
Unspecified	49 (3.7%)	15 (4.6%)	
Principal Antipsychotic			$X^2=9.802, p=0.0017$
Typical	237 (18%)	35 (10.6%)	
Atypical	1080 (82%)	294 (89.4%)	
Antipsychotics Pattern			$X^2=9.30, p=1$
Monotherapy	398 (30.2%)	99 (30.1%)	
Polypharmacy	919 (69.8%)	230 (69.9%)	
Neuropsychiatric co-medication	1080 (82%)	270 (82%)	$X^2=0, p=1$
Anticonvulsants	419 (31.8%)	113 (34.3%)	
Anticholinergics	428 (32.5%)	91 (27.7%)	
Anxiolytics	664 (50.4%)	148 (45%)	
Hypnotics / sedatives	426 (32.3%)	110 (33.4%)	
Antidepressants	481 (36.5%)	138 (42%)	
Presence of psychiatric co-morbidity	501 (38%)	143 (43.5%)	$X^2=3.03, p=0.082$
Affective disease	26 (2%)	11 (3.3%)	
Personality disease	29 (2.2%)	9 (2.7%)	
Intellectual disability	20 (1.5%)	9 (2.7%)	
Substance abuse consumption disease	387 (29.4%)	88 (26.7%)	
Presence of consumption of substances	414 (31.43%)	99 (30%)	$X^2=3.6, p=0.058$
Tobacco	343 (26%)	80 (24.3%)	
Alcohol	106 (8%)	16 (4.8%)	
Cannabis	70 (5.3%)	19 (5.8%)	
Cocaine	23 (1.7%)	8 (2.4%)	

Figure 1. **Frequency of patients treated with LAI**

